Transcode Therapeutics RNAZ

Drug Manufacturers - General, Healthcare

$1.77

+3.21%

Market cap: $30M
PE: n/m; one or more of the four quarters through 2026-06-30 missing
Forward PE: n/m; not a meaningful number
Price to sales: n/m; not a meaningful number
EV/EBIT: n/m; not a meaningful number
Revenue, 12 months: n/m; not a meaningful number
Net margin: n/m; not a meaningful number
Free cash flow yield: n/m; not a meaningful number

Charts

Financials

Income statement for RNAZ, by quarter
Income statement	Q3 FY23	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
R&D	$3.3M+10%	$3.4M+25%	$1.8M−32%	$3.1M+4%	$1.2M−63%	$3.6M+8%	$2.2M+26%	$2.6M−17%	$3.2M+158%	$5.5M+51%	$5.1M+130%	$3.7M+44%
SG&A	$2M+3%	$734K−74%	$1.5M−33%	$2M−6%	$938K−52%	$1.5M+98%	$951.7K−38%	$1.7M−19%	$1.4M+49%	$1.8M+21%	$2.2M+134%	$2.5M+53%
	−$5.3M+7%	−$4.1M−25%	−$3.3M−33%	−$5.1M−0%	−$2.2M−59%	−$5.1M+24%	−$3.2M−4%	−$4.2M−18%	−$4.6M+111%	−$16M+215%	−$17.8M+460%	−$6.8M+61%
Interest expense	$17.3K	$17.3K	$9.7K−28%	$4.5K−43%	$10.8K−38%	$1.8K−89%	$114−99%	$0	$6K−45%	$542−70%	n/a	n/a
Pre-tax income	n/a	n/a	n/a	n/a	n/a	n/a	−$12.1M	−$4.3M	n/a	n/a	−$17.6M+45%	−$6.7M+58%
	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$231.3K	$300
Net income	−$5.3M+24%	−$4.1M−20%	−$3.3M−31%	−$5.2M+20%	−$2.3M−56%	−$5.9M+45%	−$12.1M+263%	−$4.3M−18%	−$4.9M+109%	−$13.4M+127%	−$17.8M+47%	−$6.8M+58%
	−$44758.56−82%	n/a	−$597.80−100%	−$680.23−100%	−$146.06−100%	n/a	−$70.16−88%	−$5.13−99%	−$5.82−96%	n/a	−$21.28−70%	−$7.17+40%
	118+575%	n/a	5.6K+27558%	7.6K+23023%	15.9K+13322%	n/a	172.3K+2995%	833.7K+10825%	833.7K+5146%	n/a	917K+432%	957.2K+15%

R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.

EPS, diluted: 4 periods, Q1 FY20 to Q4 FY22: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 3 periods, Q4 FY20 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Transcode Therapeutics' size, closest first.

Company	Market cap	PE	Its 10y median PE	P/S	Revenue growth	Net margin
RNAZTranscode Therapeutics	$30M	n/m	n/a	n/m	n/m	n/m
ATNMActinium Pharmaceuticals	$47.8M	4.2×	3.1×	n/m	n/m	n/m
SPROSpero Therapeutics	$64.6M	10.1×	9.5×	1.4×	−3%	15.7%
LFVNLifevantage	$73.4M	14.7×	19.6×	0.4×	−20%	2.8%
NATRNatures Sunshine Products	$213.8M	12.0×	20.6×	0.4×	+7%	3.7%
Peer median	$69M	11.1×	14.5×	0.4×	−3%	3.7%